RWA Wealth Partners LLC Boosts Stock Holdings in Eli Lilly and Company $LLY

RWA Wealth Partners LLC increased its position in shares of Eli Lilly and Company (NYSE:LLY) by 49.0% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 64,533 shares of the company’s stock after buying an additional 21,231 shares during the quarter. Eli Lilly and Company makes up 0.6% of RWA Wealth Partners LLC’s portfolio, making the stock its 25th largest holding. RWA Wealth Partners LLC’s holdings in Eli Lilly and Company were worth $50,305,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Disciplined Investors L.L.C. grew its position in shares of Eli Lilly and Company by 15.7% during the 2nd quarter. Disciplined Investors L.L.C. now owns 339 shares of the company’s stock valued at $264,000 after acquiring an additional 46 shares during the period. Bensler LLC boosted its position in Eli Lilly and Company by 5.5% during the second quarter. Bensler LLC now owns 17,927 shares of the company’s stock worth $13,974,000 after purchasing an additional 934 shares in the last quarter. AE Wealth Management LLC grew its holdings in Eli Lilly and Company by 8.9% in the second quarter. AE Wealth Management LLC now owns 68,235 shares of the company’s stock valued at $53,193,000 after purchasing an additional 5,592 shares during the period. Stokes Family Office LLC increased its position in shares of Eli Lilly and Company by 2.3% in the second quarter. Stokes Family Office LLC now owns 4,208 shares of the company’s stock valued at $3,280,000 after buying an additional 96 shares in the last quarter. Finally, Paradigm Asset Management Co. LLC increased its position in shares of Eli Lilly and Company by 200.0% in the second quarter. Paradigm Asset Management Co. LLC now owns 1,050 shares of the company’s stock valued at $819,000 after buying an additional 700 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. HSBC increased their target price on Eli Lilly and Company from $700.00 to $800.00 in a research report on Wednesday, October 1st. DZ Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 14th. Sanford C. Bernstein reissued an “outperform” rating on shares of Eli Lilly and Company in a research note on Monday. Leerink Partners restated a “market perform” rating and set a $715.00 price target on shares of Eli Lilly and Company in a research report on Thursday, August 7th. Finally, Daiwa America lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Sunday, August 17th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and eight have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $960.88.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $923.35 on Friday. The company has a market cap of $872.92 billion, a P/E ratio of 60.35, a P/E/G ratio of 1.21 and a beta of 0.43. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $955.46. The company’s 50-day moving average price is $799.97 and its 200-day moving average price is $775.76. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $17.60 billion during the quarter, compared to the consensus estimate of $16.09 billion. During the same quarter in the prior year, the firm earned $1.18 EPS. Eli Lilly and Company’s quarterly revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, sell-side analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be given a dividend of $1.50 per share. The ex-dividend date is Friday, November 14th. This represents a $6.00 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 29.35%.

Insider Buying and Selling

In related news, EVP Daniel Skovronsky purchased 1,000 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The shares were acquired at an average price of $634.40 per share, for a total transaction of $634,400.00. Following the acquisition, the executive vice president directly owned 137,660 shares in the company, valued at approximately $87,331,504. The trade was a 0.73% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Gabrielle Sulzberger acquired 117 shares of the company’s stock in a transaction that occurred on Tuesday, August 12th. The stock was purchased at an average cost of $641.18 per share, with a total value of $75,018.06. Following the acquisition, the director directly owned 2,703 shares of the company’s stock, valued at $1,733,109.54. This trade represents a 4.52% increase in their position. The SEC filing for this purchase provides additional information. Over the last three months, insiders purchased 4,314 shares of company stock worth $2,766,929. 0.14% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.